Lupin Q4 FY26 PBT jumps 115% to Rs 19,280 million

U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit

Neuland Labs and LIR Life partner on next-gen transdermal GLP-1 obesity therapy platform

LIR Life is working on a patch-based, transdermal delivery system for GLP-1 therapies targeting obesity

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy

Venus Remedies gets marketing authorization for Ceftriaxone in Argentina

Approval strengthens the company’s growing international anti-infective portfolio

China poised to launch world’s first CAR-T therapy for gastric cancer

As per GlobalData, CARsgen’s satri-cel could mark a major breakthrough in solid tumor treatment as competition intensifies

ADMA Biologics wins FDA nod to expand ASCENIV use in young children

Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation

Pfizer powers ahead in 2026 with strong Q1 results as pipeline momentum builds

The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook

Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth